AT9283

Item no.	M1655-25mg
Manufacturer	AbMole
CASRN	896466-04-9
Amount	25mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	>99.0%
Citations	A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Arkenau, et al . Ann Oncol. 2012 May,23(5):1307-13. PMID: 22015452 . AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Qi W, et al . Int J Cancer. 2012 Jun 15,130(12):2997-3005. PMID: 21796626 . AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. Kimura S Curr Opin Investig Drugs. 2010 Dec,11(12):1442-9. PMID: 21154126 . AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Dawson, et al . Br J Haematol. 2010 Jul,150(1):46-57. PMID: 20507304 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Similar products	AT9283
Available
Target Information	Aurora Kinase
Molecular Weight	381, 43
Solubility	DMSO 61 mg/mL
Bioactivity information	AT9283 is a potent inhibitor of several protein kinases, including Aurora A, Aurora B, Janus kinase 2 (JAK2), JAK3, and ABL.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1655-25mg-safety-datasheet.pdf